Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcoma
- 11 February 2011
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 58 (2) , 181-184
Abstract
Background: Circulating endothelial cells (CECs) have been detected at increased numbers in patients with solid cancers. CECs have not been systematically evaluated in patients with osteosarcoma.Procedure: Patients 12 months to 30 years of age with newly diagnosed high‐grade osteosarcoma were eligible for this prospective cohort study. Patients provided a single blood sample at study entry for CEC quantification by flow cytometry at a single reference laboratory. CECs were defined as CD146+, CD31+, CD45−, and CD133−. CEC progenitor cells (CEPs) were defined as CD146+, CD31+, CD45−, and CD133+.Results: Eighteen patients enrolled (11 males; median age 16 years; range 5–21 years). CEC counts did not differ between patients with osteosarcoma compared to seven pediatric healthy controls (median 645 cells/ml, range 60–5,320 cells/ml vs. 1,670 cells/ml, range 330–4,700 cells/ml, respectively; P = 0.12). CEP counts did not differ between patients compared to controls (median 126 cells/ml, range 0–5,320 cells/ml vs. median 260 cells/ml, range 0–10,670 cells/ml, respectively; P = 0.69). CEC and CEP counts did not correlate with metastatic status, tumor size, or histologic response to neoadjuvant chemotherapy.Conclusions: CEC and CEP levels are not increased in patients with osteosarcoma compared to healthy controls. CECs and CEPs do not correlate with clinical features of osteosarcoma. Alternative novel markers of disease burden and response are needed in this disease. Pediatr Blood Cancer 2012; 58: 181–184.Keywords
Funding Information
- Campini Foundation
- Friends of Dana-Farber
- NIH/NCRR/OD UCSF-CTSI (KL2 RR024130)
This publication has 24 references indexed in Scilit:
- Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patientsAnnals of Oncology, 2004
- Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcomaBritish Journal of Cancer, 2002
- Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group ProtocolsJournal of Clinical Oncology, 2002
- Resting and activated endothelial cells are increased in the peripheral blood of cancer patientsBlood, 2001
- Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursorsBlood, 2000
- Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis.2000
- Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts.2000
- Different patterns of angiogenesis in sarcomas and carcinomas.1999
- Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcomaEuropean Journal of Cancer, 1999
- Demonstration of receptors for a PDGF-like mitogen on human osteosarcoma cellsBiochemical and Biophysical Research Communications, 1985